Filgrastim Biosimilars Market Report 2026

Filgrastim Biosimilars Market Overview

• Filgrastim Biosimilars market size has reached to $1.19 billion in 2025 • Expected to grow to $2.09 billion in 2030 at a compound annual growth rate (CAGR) of 11.9% • Growth Driver: Surge In Cancer Cases Fueling Growth Due To Rising Need For Supportive Therapy • Market Trend: Amneal Pharmaceuticals' Fylnetra Marks A New Era Of Accessible Healthcare With Recombinant DNA Technology • North America was the largest region in 2025 and Middle East is the fastest growing region.

What Is Covered Under Filgrastim Biosimilars Market?

Filgrastim biosimilars refer to a biosimilar that is intended to treat patients who suffer bone marrow damage from extremely high radiation doses in a manner similar to how it helps cancer patients by stimulating the formation of white blood cells, making patients less susceptible to infections. The main types of manufacturing for the filgrastim biosimilar market are in-house manufacturing and contract manufacturing organization. A contract manufacturing organization, also known as a contract development and manufacturing organization, is a corporation that provides entire services to other pharma firms on a contractual basis, from drug discovery to drug production. The different applications include oncology, chronic and autoimmune diseases, blood disorders, growth hormone deficiency, infectious diseases, and others, and are distributed through various channels such as hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Filgrastim Biosimilars Market Growth Forecast?

The filgrastim biosimilars market size is expected to see rapid growth in the next few years. It will grow to $2.09 billion in 2030 at a compound annual growth rate (CAGR) of 11.9%. The growth in the forecast period can be attributed to launch of next-generation filgrastim biosimilars, expansion of contract manufacturing partnerships, increasing adoption in chronic and autoimmune diseases, rising government support and reimbursement policies, development of patient-centric distribution and delivery models. Major trends in the forecast period include rising adoption of filgrastim biosimilars in oncology and blood disorder treatments, expansion of contract manufacturing organizations for biosimilar production, increasing use of in-house vertically integrated manufacturing facilities, growing preference for hospital and retail pharmacy distribution channels, focus on cost-effective biologics and access in emerging markets.

Global Filgrastim Biosimilars Market Segmentation

1) By Type Of Manufacturing: In-House Manufacturing, Contract Manufacturing organization 2) By Application: Oncology, Chronic And Autoimmune Diseases, Blood Disorders, Other Applications 3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy Subsegments: 1) By In-House Manufacturing: Proprietary In-House Manufacturing Facilities, Company-Owned Production Plants, Vertically Integrated Manufacturing 2) By Contract Manufacturing Organization: Full-Service Contract Manufacturing, Fill and Finish Services, API (Active Pharmaceutical Ingredient) Manufacturing, Specialized Biosimilar Manufacturing Services

What Is The Driver Of The Filgrastim Biosimilars Market?

The rising cancer incidence is expected to drive the growth in the filgrastim biosimilars market going forward. Cancer refers to a group of diseases marked by the uncontrolled growth and spread of abnormal cells in the body, driven by genetic mutations that disrupt normal cell regulation. Rising cancer incidence is partly due to population aging, as more people live longer and face a higher likelihood of genetic mutations that lead to cancer. Filgrastim biosimilars help cancer patients by boosting white blood cell production, reducing the risk of chemotherapy-induced neutropenia, and enabling safer, more continuous cancer treatment. For instance, in October 2025, according to National Health Service (NHS), a UK-based government health agency, there were 354,820 new cancer diagnoses in 2023, an average of 972 per day, which is 8,605 more than in 2022. Therefore, the rising cancer incidence is driving the filgrastim biosimilars industry.

Key Players In The Global Filgrastim Biosimilars Market

Major companies operating in the filgrastim biosimilars market are Teva Pharmaceutical Industries Ltd, Biocon Limited, Intas Biopharmaceuticals, Dr. Reddy's Laboratories, Cadila Healthcare Ltd, Reliance Life Science Pvt. Ltd, Gennova Biopharmaceuticals (Emcure), Sandoz Pty Ltd, Mylan, Lupin Limited, Coherus Biosciences Inc., Tonghua Dongbaoare, Adello Biologics, Apobiologix (Apotex), Hospira, Tanvex BioPharma.

Global Filgrastim Biosimilars Market Trends and Insights

Major companies operating in the filgrastim biosimilar market are developing innovative products with advanced technologies such as recombinant DNA technology to produce biosimilars. Recombinant DNA technology is a process that involves the creation of hybrid or chimeric DNA by inserting a foreign sequence into the DNA of an organism. For instance, in May 2023, Amneal Pharmaceuticals, a US-based pharmaceutical company launched FYLNETRA (pegfilgrastim-pbbk), a biosimilar to Amgen’s NEULASTA, in the United States indicated for the treatment and prevention of febrile neutropenia. It promotes the expansion and specialization of neutrophils originating from dedicated precursor cells, triggers their maturation, and improves the viability and efficiency of fully developed neutrophils, leading to dosage-dependent rises in neutrophil counts. The launch of Fylnetra contributes to the next wave of affordable medicines and drives access across patients, providers, and payors.

What Are Latest Mergers And Acquisitions In The Filgrastim Biosimilars Market?

In August 2025, Intas Pharmaceuticals Ltd., an India-based pharmaceutical company, partnered with Accord Healthcare Inc., to acquire the Udenyca business from Coherus Biosciences, Inc. for an undisclosed amount. With this partnership, Intas Pharmaceuticals and Accord Healthcare aim to become one of the largest global suppliers of pegfilgrastim by combining Intas’ and Accord’s commercialization and distribution capabilities with Coherus’ established product portfolio, enhancing patient access, supporting continued growth, and ensuring supply continuity in the US and global markets. Coherus Biosciences Inc. is a US-based biotechnology company that specializes in the development, manufacture, and commercialization of biosimilar therapies for oncology and autoimmune indications.

Regional Insights

North America was the largest region in the filgrastim biosimilar markets market in 2025. Middle East is expected to be the fastest growing region in the global filgrastim biosimilar markets market during the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Filgrastim Biosimilars Market?

The filgrastim biosimilar markets consist of sales of Zarxio, Nivestym, and Releuko. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Filgrastim Biosimilars Market Report 2026?

The filgrastim biosimilars market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the filgrastim biosimilars industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.